Thomas Carey is the founder of Perspective Group, where he also served as Managing Partner until late 2022. Perspective Group focuses on innovative life sciences companies, specializing in board advisory and executive search.

Tom previously spent 15 years at two leading executive search firms. Most recently he led Spencer Stuart’s efforts in life sciences board of director advisory and recruitment services. Prior to that, at Russell Reynolds, he was co-leader of the global healthcare practice, and earlier he led the firm’s biopharmaceuticals practice in the Americas. Before entering the executive search industry, Tom served as CFO of various private and public healthcare companies. He began his career as an investment banker in M&A.

Tom has notable board experience, serving on the Board of SomaLogic, Inc., a publicly traded life sciences tools company (Nasdaq:SLGC) until its merger with Standard BioTools, and previously on the Board of Exact Sciences Corporation (Nasdaq:EXAS), a publicly traded cancer diagnostics company, and as the Chair of the Board of Vital Bioscience, Inc., a venture capital backed point-of-care diagnostics company. Tom also serves on the regional board of the American Cancer Society.

Tom received his bachelor’s degree in physics from the College of the Holy Cross and his MBA from the Kellogg Graduate School of Management at Northwestern University.

Michael Egholm, PhD, joined Standard BioTools in April 2022 as President and Chief Executive Officer and a member of our Board of Directors. He previously served as the Chief Technology Officer of Danaher Life Sciences as well as the founder and leader of Danaher’s corporate venture fund. Michael completed his PhD and master’s degree in chemistry at the University of Copenhagen.

Frank Witney PhD, joined our Board of Directors in April 2022. He has served as an Operating Partner at Ampersand Capital Partners, a private equity firm, since September 2016. From July 2011 to March 2016, Witney served as President and Chief Executive Officer of Affymetrix, Inc., a provider of life sciences and molecular diagnostic products, until Affymetrix was acquired by Thermo Fisher Scientific Inc. From April 2009 to May 2011, he was President and Chief Executive Officer of Dionex Corporation, a provider of analytical instrumentation and related accessories and chemicals. From December 2008 to April 2009, Witney served as Affymetrix’s Executive Vice President and Chief Commercial Officer. From July 2002 to December 2008, he was President and Chief Commercial Officer of Panomics Inc. Frank currently serves on the boards of directors of PerkinElmer Inc. (NYSE:PKI), Codex DNA (Nasdaq:DNAY), Cerus Corporation (Nasdaq:CERS), Emulate, Inc., Leinco Technologies, Inc., and JumpCode Genomics, Inc. He has previously served on the boards of Gyros Protein Technologies, RareCyte, Inc., GeneOptx, Canopy Bioscience, and Nexcelom Inc. Frank earned a BS in microbiology from the University of Illinois and an MS in microbiology and a PhD in molecular and cellular biology from Indiana University. 

Fenel Eloi is a seasoned executive in the life sciences sector. He is currently the Managing Partner of P&M Capital Partners, LLC, a private equity firm engaged in angel investing of life sciences startups. He was the Chief Operating Officer and Chief Financial Officer of Cell Signaling Technology, Inc., a privately held life sciences company, from September 2005 to March 2018. Prior to that, he was the Chief Operating Officer of Interleukin Genetics, Inc., a formerly Nasdaq-listed diagnostics company, for five years. Prior to Interleukin, he was Chief Financial Officer at LifeCell Corp. and Genome Therapeutics Corp., both formerly Nasdaq-listed companies, for a combined period of 12 years. Fenel currently serves on the Board of 908 Devices Inc., a Nasdaq-listed company. He also serves on the boards of Vaxess Technologies Inc., Ultivue, Inc., and Mitotherapeutix, LLC, all private life sciences companies. He also serves on the board of VIC Technology Venture Development, a life sciences venture investment company. During his professional career, Fenel has scaled up operations, expanded businesses both organically and through strategic partnerships and completed a number of public and private financing transactions. His leadership experience ranges from startup companies to multinationals. Fenel has an MBA from Anna Maria College and a BA in Business and Finance from Lee University.

Kathy is the Chief Administrative Officer of 23andMe, the world leader in consumer health, where she leads its complex legal, regulatory affairs, human resources, and supply chain operations and manages a team of 75 employees. She is globally recognized for her effectiveness, having successfully pioneered the first FDA clearance for over-the-counter genetic testing and eight further FDA clearances expanding consumer access to cancer risk and pharmacogenetic information, overcoming one of the most publicized FDA warning letters and enabling the relaunch and expansion of the company’s core products. She is called upon by regulators and legislators around the world to lead on these topics. She has successfully managed complex teams under regular and crisis conditions and has negotiated numerous transactions and private and public financings totaling more than $1 billion. 

Regularly recognized as one of the Bay Area’s most influential women by the both the San Francisco and Silicon Valley Business Journals, Kathy is ranked by Chambers as among the most influential General Counsels in the US. She is active in key industry groups including AdvaMed and the Fast Company Impact Council and is a frequent speaker on genomics, privacy, and regulation, including keynotes at RSA Conference 2020 and FedTalks 2019. 

She sits on the boards of Sophia Genetics  and SomaLogic and served on the Board of Decipher Biosciences, Inc. prior to its merger with Veracyte, Inc. Her broad knowledge of corporate governance and investor expectations pairs with her commitment to management and growth in uncharted settings. 

During her 20 years’ experience as an executive officer and corporate secretary of public biotechnology companies Genomic Health, Inc. and Monogram Biosciences Inc., Kathy developed her passion for the need and opportunity for technology to improve the lives of patients. 
She graduated summa cum laude from the University of California, Riverside and received her JD from Hastings College of the Law. 

Kathy lives in Woodside, CA, with her husband and son. She spends her free time traveling with her family and friends, reading historical biographies, and supporting local organizations dedicated to addressing the problems of homelessness and food insecurity. 
 

Troy Cox, former Chief Executive Officer of Foundation Medicine, is the Chairman of SOPHiA GENETICS SA (Nasdaq:SOPH), Vice Chairman at LetsGetChecked, and Independent Board Director at Zymeworks Inc. (Nasdaq:ZYME) and Biosplice Therapeutics Inc. as well as at non-profits MassBio and Dream Foundation. He was on the Board of SomaLogic, Inc., (Nasdaq:SLGC) until its merger with Standard BioTools.

Troy was the President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche valuing FMI at $5.3 billion. Prior to Foundation Medicine, he served as Senior Vice President and Officer at Genentech, Inc. leading US BioOncology for a period of unprecedented growth to over $12 billion, participating in the launch of nearly half of the products from the world’s oncology leader, and steering the Roche Genentech R&D portfolio. Before Genentech, he held executive and senior roles of increasingly broad accountabilities including President of UCB BioPharmaceuticals, Senior Vice President of Sanofi-Aventis, and diverse foundational roles at Schering-Plough.

Troy received his BBA in finance from the University of Kentucky and his MBA from the University of Missouri.

Eli Casdin founded Casdin Capital in 2011 and serves as Chief Investment Officer. Casdin Capital engages as a team of productive investor-partners, helping to fuel the visions of industry leaders by adding expertise and experience to their funding. Focused on emergent technologies in life sciences for more than two decades, Eli has been active in both private and public capital markets, following a passion for analyzing and investing in new technologies and business models within the life sciences and healthcare industries. Prior to founding Casdin Capital, he served as vice president at Alliance Bernstein’s thematic investment arm, focusing personally on new technologies for the life sciences and healthcare sectors. While there he co-authored the 2011 black book The Dawn of Molecular Medicine, detailing the then-early yet accelerating wave of innovations transforming healthcare and creating opportunity for investors in areas from testing to targeted medicine, diagnostics, and industrial agriculture. Earlier, he worked as a financial analyst at Bear Stearns and Cooper Hill Partners, a healthcare-focused investment firm. Eli earned a BS from Columbia University and an MBA from Columbia Business School. Today, he serves as a director or an observer on various boards for a number of public and private life sciences companies, trade groups, and academic institutes including Rockefeller University, the New York Genome Center, and The Columbia University School of General Studies.